Targeting IRAK1 signaling in PCa and other prostate pathologies comes with multiple benefits in impeding chronic inflammatory effects and also dampening the tumorigenic activities of the NF-κB transcriptional factors downstream of IRAK1 in the inflammatory cascade. The gene discussed is IRAK1; the disease is urogenital neoplasm.